Evidence map›Paper›PMID 34717683›Full record

ArticleJournal of orthopaedic surgery and research2021

Doxorubicin inhibits osteosarcoma progression by regulating circ_0000006/miR-646/ BDNF axis.

Abulimiti Amuti, Dehu Liu, Ayiguli Maimaiti, Yao Yu, Yalikun Yasen, Haoguang Ma, Rui Li, Shurong Deng, Fei Pang, Youliang Tian

Open access · goldAbstract read
In one paragraph

Article in Journal of orthopaedic surgery and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Mesenchymal stroma drives axonogenesis and nerve-induced aggressiveness in osteosarcoma.Journal of experimental & clinical cancer research : CR · 2025
    Article
  5. Article
  6. Article
  7. Osteosarcoma in a ceRNET perspective.Journal of biomedical science · 2024
    Review
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Abulimiti Amuti *Department of Orthopaedics, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Dehu Liu *Department of Osteology, Tai'an Traditional Chinese Medicine Hospital, Taian, Shandong, China.
Ayiguli MaimaitiDepartment of Orthopaedics, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Yao YuSix Subjects of Hand Surgery, Affiliated Central Hospital of Shenyang Medical College, Shenyang, Liaoning, China.
Yalikun YasenDepartment of Orthopaedics, The Second Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Haoguang MaDepartment of Surgery, Hot Spring Sanatorium of Linyi, Linyi Hedong Central Hospital, Linyi, Shandong, China.
Rui LiDepartment of Joint Surgery, The Fourth Hospital of Baotou, Baotou City, Mongolia, China.
Shurong DengDepartment of Pharmacy, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
Fei PangDepartment of Orthopaedics, Shaoxing People's Hospital, No. 568 North Zhongxing Road, Yuecheng District, Shaoxing City, 312000, Zhejiang Province, China. jrxvtw@163.com.
Youliang TianDepartment of Rehabilitation Medicine and Physiotherapy, PLA Strategic Support Force Characteristic Medical Center, No. 9 Anxiang North Lane, Chaoyang District, , Beijing, 100101, China. epeqyf@163.com.
Second Affiliated Hospital of Xinjiang Medical University · CNBeijing Chaoyang Emergency Medical Center · CNCentral Hospital Affiliated to Shenyang Medical College · CNFirst Affiliated Hospital of Jinan University · CNLinyi People's Hospital · CNShaoxing People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOsteosarcoma (OS) is the most common aggressive bone tumor in children and teenagers. Doxorubicin (DOX) is a chemotherapeutic drug for OS. This study aims to reveal the effects and underneath mechanism of DOX treatment in OS progression.

methodsThe expression of circular_0000006 (circ_0000006), microRNA-646 (miR-646) and brain-derived neurotrophic factor (BDNF) was detected by quantitative real-time polymerase chain reaction (qRT-PCR). BDNF protein expression was determined by western blot. Cell proliferation was illustrated by cell counting kit-8 (CCK-8) and cell colony formation assays. Cell migration and invasion were revealed by transwell migration and wound-healing assays and transwell invasion assay, respectively. Cell apoptosis was demonstrated by flow cytometry analysis. The binding relationship of miR-646 and circ_0000006 or BDNF was predicted by circRNA interactome and targetscan online database, respectively, and verified by dual-luciferase reporter assay. The effects of circ_0000006 knockdown on tumor growth in vivo were manifested by in vivo tumor formation assay.

resultsCirc_0000006 expression and the mRNA and protein levels of BDNF were dramatically upregulated, and miR-646 expression was effectively downregulated in OS tissues or cells compared with control groups. Circ_0000006 expression and BDNF protein expression were lower, and miR-646 expression was higher in DOX treatment groups than in control groups in OS cells. Circ_0000006 knockdown repressed cell proliferation, migration and invasion, whereas promoted cell apoptosis under DOX treatment in OS cells; however, these effects were attenuated by miR-646 inhibitor. Additionally, circ_0000006 sponged miR-646 to bind to BDNF. Circ_0000006 silencing suppressed tumor growth in vivo.

conclusionCirc_0000006 knockdown promoted DOX-mediated effects on OS development by miR-646/BDNF pathway, which provided a theoretical basis in treating OS with DOX.

Indexed as

OsteosarcomaBrain-Derived Neurotrophic FactorDisease ProgressionDoxorubicinGene Expression Regulation, NeoplasticHumansMicroRNAsRNA, CircularBDNF protein, humanBrain-Derived Neurotrophic FactorDoxorubicinMicroRNAsMIRN646 microRNA, humanRNA, CircularBDNFcirc_0000006DOXmiR-646Osteosarcoma

Identifiers

PMID34717683
PMCPMC8557021
OpenAlexW3210982156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.